Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial

The lung immune prognostic index (LIPI) is proposed to differentiate prognosis and treatment benefit from immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC). There is minimal information on the predictive importance with first-line, combination ICI approaches. In post...

Full description

Bibliographic Details
Main Authors: Ashley M. Hopkins, Ganessan Kichenadasse, Ahmad Y. Abuhelwa, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
atezolizumab
non-small cell lung cancer
overall survival
lung immune prognostic index
Online Access:https://www.mdpi.com/2072-6694/13/5/1176

Internet

https://www.mdpi.com/2072-6694/13/5/1176

Similar Items